News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rinat Neuroscience Corporation Begins Clinical Testing Of Potential First-In-Class Pain Therapeutic



10/19/2005 5:08:49 PM

Rinat Neuroscience, a privately held biotechnology company, today announced the initiation of Phase 1 human safety testing of the company's lead investigational therapeutic, RI 624. The company discovered and is developing RI 624, a humanized monoclonal antibody that inhibits nerve growth factor (NGF), for the treatment of both acute and chronic pain.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES